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Abstract: Background: People living with human immunodeficiency virus (HIV) (PLWH) form
a vulnerable population for the onset of infective endocarditis (IE). We aimed to analyze the
epidemiological trend of IE, as well as its microbiological characteristics, in PLWH during the
combined antiretroviral therapy era in Spain. Methods: We performed a retrospective study
(1997–2014) in PLWH with data obtained from the Spanish Minimum Basic Data Set. We selected 1800
hospital admissions with an IE diagnosis, which corresponded to 1439 patients. Results: We found
significant downward trends in the periods 1997–1999 and 2008–2014 in the rate of hospital admissions
with an IE diagnosis (from 21.8 to 3.8 events per 10,000 patients/year; p < 0.001), IE incidence (from
18.2 to 2.9 events per 10,000 patients/year; p < 0.001), and IE mortality (from 23.9 to 5.5 deaths per
100,000 patient-years; p < 0.001). The most frequent microorganisms involved were staphylococci
(50%; 42.7% Staphylococcus aureus and 7.3% coagulase-negative staphylococci (CoNS)), followed
by streptococci (9.3%), Gram-negative bacilli (8.3%), enterococci (3%), and fungus (1.4%). During
the study period, we found a downward trend in the rates of CoNS (p < 0.001) and an upward
trends in streptococci (p = 0.001), Gram-negative bacilli (p < 0.001), enterococci (p = 0.003), and
fungus (p < 0.001) related to IE, mainly in 2008–2014. The rate of community-acquired IE showed a
significant upward trend (p = 0.001), while the rate of health care-associated IE showed a significant
downward trend (p < 0.001). Conclusions: The rates of hospital admissions, incidence, and mortality
related to IE diagnosis in PLWH in Spain decreased from 1997 to 2014, while other changes in clinical
characteristics, mode of acquisition, and pathogens occurred over this time.
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1. Introduction
Infective endocarditis (IE) is uncommon but causes high morbidity and mortality [1]. In recent
decades, the epidemiology of IE has evolved in developed countries. The population at risk of infection
used to be people with rheumatic valvular heart disease, those with a history of dental interventions
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or intravenous drug users. However, in recent decades, the incidence of IE has increased in elderly
people and patients who undergo in-hospital procedures [1,2]. In Spain, Olmos et al. found that the
IE incidence in the general population increased from 2.72 in 2003 to 3.49 per 100,000 person-years
in 2014, in a work published with data from the Minimum Basic Data Set (MBDS) from Spain [3].
Several population-based studies in Europe have also showed an increase in IE incidence in the general
population [4–7] and in intensive care units [8] over time. Regarding the responsible infectious agents,
streptococci and staphylococci are the most common cause of IE (approximately 80%) in most developed
countries, but the proportion of these two microorganisms varies by region and year. Enterococci are the
next most common cause of IE and, less commonly, fungi and Gram-negative bacilli [1].
During the history of the human immunodeficiency virus (HIV) epidemic, approximately 75
million people worldwide have been infected with HIV and, currently, there are approximately
37 million people living with HIV (PLWH) [9]. In the absence of combined antiretroviral therapy
(cART), HIV-infected subjects have a progressive CD4+ T cell loss and a wide range of immunological
abnormalities, which lead to an increased risk of infections [9]. Since the mid-90s, cART has led
to durable HIV suppression, which allowed immune recovery and a dramatic reduction in the
risk for developing acquired immune deficiency syndrome (AIDS) [9]. However, despite effective
cART, the HIV-infected population is ageing prematurely, and the onset of frailty occurs at an earlier
age [10]. Thus, HIV-infected patients on cART, even after achieving an acceptable immunological
status, still remain a “fragile” population [11] with a higher risk of bloodstream infections and IE [12].
The CD4+ T-cell count is a key factor in relation to the risk of infection in PLWH [13,14], even
in HIV-infected patients on cART [15], since a dysregulation of the immune system predisposes an
individual to invasive infections and the development of IE [12,13,16]. HIV-infected patients with
CD4 cell counts >500 cells/µL had a higher risk of infections compared to those with a CD4 count
>750 cells/µL [15]. Thus, the viability of cART and the effectiveness of these antiretroviral treatments
may have been a key factor in the epidemiology of IE in the last two decades. There is little knowledge
of IE epidemiology in PLWH during the cART era in regards to rates of hospital admission, incidence,
and mortality in large cohorts or in population studies.
2. Objective
We aimed to analyze the epidemiological trends of IE, as well as the associated microbiological
characteristics, in PLWH during the cART era (1997–2014) in Spain by using the Minimum Basic Data
Set (MBDS) of the Spanish National Health Service.
3. Materials and Methods
3.1. Study Population
A nationwide population-based retrospective study was performed in HIV-infected patients
with an IE diagnosis between January 1, 1997 and December 31, 2014 in Spain. The study period
was stratified into four calendar periods: (a) 1997–1999; (b) 2000–2003; (c) 2004–2007; (d) 2008–2014.
All subjects were older than 18 years.
Data were obtained from discharge records in the Spanish MBDS of the Ministry of Health,
Consumption and Social Welfare (MHCSW). Data were requested in 2017, but the MHCSW gave
us the historical series until 2014 because the Spanish MBDS releases the data with a 2–3-year lag.
Then, debugging the acquired database was carried out. The MBDS is an administrative database,
which contains epidemiological and clinical information recorded at the time of hospital discharge.
The discharge diagnoses and procedures performed during the hospital stay were recorded according
to the International Classification of Diseases, 9th ed, Clinical Modification (ICD-9-CM). The MDBS
has a coverage of 92% of all Spanish hospitals, 84.14% of which are public hospitals and 15.86% are
private hospitals [17]. The Spanish MHCSW ensured the data quality by establishing protocols for
record keeping and conducting periodic audits on the MBDS.
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The clinical status of patients was defined by ICD-9-CM codes (see Supplementary Table S1).
Overall, 34,398 hospital admissions with an IE diagnosis were found from 1997 to 2014 in the Spanish
MBDS. Among those, 1800 were admissions of HIV-infected patients (ICD-9-CM codes: 042 or V08),
which corresponded to 1439 patients with at least one hospital admission (Figure 1).
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3.2. Ethics Statement
The health-related personal data were requested by the MHCSW from Spanish hospitals, according
to Spanish legislation [18]. Additionally, the identification of the patient was encrypted and anonymized.
Therefore, the signed pa e t’s co sent was not needed because the MBDS information is mandatory
and it is an anonymous dataset. The MHCSW and the Research Ethics Committee (Comité de Ética de
la Investigación y de Bienestar Animal; CEI PI 69_2012) of the Instituto de Salud Carlos III (Madrid,
Spain) approved our study. The signed patient’s consent was not needed because the Minimum Basic
Data Set contains mandatory information and it is an anonymous dataset.
3.3. Study Variables and Statistical Analysis
The main outcome was the IE diagnosis (ICD-9-CM codes: 421.0, 421.1, and 421.9), which was
diagnosed according to standard procedures in each hospital of the Spanish National Health System.
In this study, we defined the following utcome variabl s and r tes related to IE: (i) hospital admission
with an IE diagnosis (any admission that had a diagnosis f IE included in any position.); (ii) first
IE diagnosis or index episode (incidence of new IE diagnosis, patients readmitted with a later IE
diagnosis were discarded); (iii) in-hospital death among patients with IE diagnosis (mortality and
case fatality rate). The rate f hospital ad issions (episodes per 10,000 person-years), incidence (new
episodes per 10,000 person-years), and mortality (deaths per 100,000 pers n-years) were calculated
by the ratio between the number of events and the number of persons at risk within each calendar
period, according to the number of PLWH in Spain (reference population), which was provided by the
National Centre of Epidemiology (Instituto de Salud Carlos III, Madrid, Spain) (see Supplementary
Table S2) [19]. The case fatality rate was calculated as the ratio between the number of deaths and the
number of patients with an IE diagnosis (percentage, %).
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Next, we analyzed the rate of hospital admissions with an IE diagnosis according to mode of
acquisition: (i) community-acquired IE (only main diagnosis of IE) and (ii) health care-associated IE
(there was no main diagnosis of IE, but there was a secondary diagnosis). We also analyzed the presence
of codes for specific microorganisms in the hospital admissions with an IE diagnosis (see Supplementary
Table S1): staphylococci (coagulase-negative staphylococci (CoNS) and Staphylococcus aureus),
streptococci, enterococci, Gram-negative bacilli, and fungus. The rate of each microorganism was
calculated as the ratio (percentage) between the number of times the microorganism was found and
the number of those cases with a diagnosis of IE.
The chi-squared test and Fisher’s exact test were used to analyze categorical data and proportions,
as required. Continuous variables were studied using the t-Test or Mann–Whitney U test. The Extended
Mantel–Haenszel Chi-Square was used to evaluate the temporal trends of rates. All statistical tests
were performed with the Statistical Package for the Social Sciences (SPSS) 22.0 software (IBM Corp.,
Chicago, IL, USA) and were considered significant with values of p < 0.05 (two-tailed).
4. Results
4.1. Characteristics of the Study Population
Table 1 shows the characteristics of 1800 hospital admissions of HIV-infected patients with an IE
diagnosis in Spain (1997 to 2014).
Overall, most of the patients were men (83%) with a median age of 36 years. When the
characteristics of the patients were stratified by calendar periods, we found a significant increase in the
age strata (p < 0.001), percentage of patients with substance abuse (drugs (<0.001), alcohol (p = 0.024),
and tobacco (p < 0.001)), and some comorbidities (diabetes (p < 0.001), hypertension (p < 0.001),
coronary artery disease (p = 0.004), liver disease (p < 0.001), chronic obstructive pulmonary disease
(p < 0.001), and chronic kidney disease (p < 0.001)). We also found an upward trend in predisposing
factors such as congenital heart disease (p = 0.008), valve surgery (p = 0.029), infection of cardiac
device or implant (p < 0.001), history of pacemaker or defibrillator placement (p = 0.025), history of
prosthetic valve replacement (p = 0.009), receiving intravenous therapy or home care (p < 0.001), and
hemodialysis (p < 0.001). Viral hepatitis was the most frequent coinfection (43.5%), particularly chronic
hepatitis C (40.1%). During the follow up, we found a significant upward trend of hepatitis B (from 4
to 10.3; p < 0.001) and chronic hepatitis C (from 14.5 to 60.3; p < 0.001). Mycobacteria was another
frequent microorganism (2.8%), but we found a significant decrease in mycobacteria infection from
1997–1999 to 2008–2014 (from 3.7 to 2.5; p < 0.001). The percentage of patients with one or more than
two organ failures was 12.7 and 2.9%, respectively, and increased during the follow up.
Table 1. Clinical and epidemiological characteristics of hospital admissions of HIV-infected patients
with infective endocarditis in Spain (1997 to 2014).
All Patients Calendar Periods
1997–1999 2000–2003 2004–2007 2008–2014 p-Value
Number of patients 1800 594 474 376 358
Male 1494 (83%) 496 (83.5%) 398 (84.3%) 302 (80.3%) 298 (83.2%) 0.454
Age, years
<30 413 (22.9%) 251 (42.3%) 86 (18.2%) 45 (12%) 31 (8.7%) <0.001
30–34 405 (22.5%) 159 (26.8%) 136 (28.8%) 68 (18.1%) 42 (11.7%) <0.001
35–39 439 (24.4%) 116 (19.5%) 135 (28.6%) 118 (31.4%) 70 (19.6%) 0.301
40–44 302 (16.8%) 50 (8.4%) 72 (15.3%) 101 (26.9%) 79 (22.1%) <0.001
>45 241 (13.4%) 18 (3%) 43 (9.1%) 44 (11.7%) 136 (38%) <0.001
Substances of abuse
Drugs 386 (21.4%) 73 (12.3%) 91 (19.3%) 110 (29.3%) 112 (31.3%) <0.001
Alcohol 16 (0.9%) 2 (0.3%) 3 (0.6%) 5 (1.3%) 6 (1.7%) 0.003
Tobacco 358 (19.9%) 56 (9.4%) 84 (17.8%) 105 (27.9%) 113 (31.6%) <0.001
Comorbidities
Diabetes 25 (1.4%) 1 (0.2%) 7 (1.5%) 5 (1.3%) 12 (3.4%) <0.001
Hypertension 25 (1.4%) 1 (0.2%) 5 (1.1%) 4 (1.1%) 15 (4.2%) <0.001
Coronary artery disease 15 (0.8%) 1 (0.2%) 2 (0.4%) 6 (1.6%) 6 (1.7%) 0.004
Peripheral vascular disease 51 (2.8%) 9 (1.5%) 15 (3.2%) 19 (5.1%) 8 (2.2%) 0.148
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Table 1. Cont.
All Patients Calendar Periods
1997–1999 2000–2003 2004–2007 2008–2014 p-Value
Cerebrovascular Disease 25 (1.4%) 5 (0.8%) 6 (1.3%) 10 (2.7%) 4 (1.1%) 0.317
Cancer 16 (0.9%) 4 (0.7%) 4 (0.8%) 2 (0.5%) 6 (1.7%) 0.256
Liver disease 186 (10.3%) 31 (5.2%) 33 (7%) 61 (16.2%) 61 (17%) <0.001
Chronic obstructive pulmonary disease 25 (1.4%) 0 (0%) 4 (0.8%) 9 (2.4%) 12 (3.4%) <0.001
Chronic kidney disease 20 (1.1%) 0 (0%) 0 (0%) 0 (0%) 20 (5.6%) <0.001
Coinfections
Mycobacteria 51 (2.8%) 22 (3.7%) 14 (3%) 6 (1.6%) 9 (2.5%) <0.001
Pneumocystis 29 (1.6%) 7 (1.2%) 10 (2.1%) 8 (2.1%) 4 (1.1%) 0.804
Hepatitis B 151 (8.4%) 24 (4%) 54 (11.4%) 36 (9.6%) 37 (10.3%) <0.001
Hepatitis C 421 (40.1%) 86 (14.5%) 185 (39.2%) 234 (62.2%) 216 (60.3%) <0.001
Predisposing factors
Congenital heart disease 8 (0.4%) 1 (0.2%) 1 (0.2%) - 6 (1.7%) 0.008
Valve surgery 75 (4.3%) 21 (2.5%) 15 (3.2%) 16 (4.3%) 23 (6.4%) 0.029
Infection of cardiac device or implant 32 (1.8%) 4 (0.7%) 7 (1.5%) 8 (2.1%) 13 (3.6%) <0.001
History of pacemaker or defibrillator placement 13 (0.7%) 2 (0.3%) 3 (0.6%) 1 (0.3%) 7 (2%) 0.025
History of prosthetic valve replacement 98 (5.8%) 25 (4.2%) 24 (5.1%) 19 (5.1%) 30 (8.4%) 0.009
Receiving intravenous therapy or home care 53 (3%) 7 (1.2%) 13 (2.8%) 16 (4.3%) 17 (4.7%) <0.001
Hemodialysis dependent 31 (1.7%) 4 (0.7%) 5 (1.1%) 4 (1.1%) 18 (5%) <0.001
Urgent admission 1593 (88.5%) 524 (88.2%) 429 (90.9%) 331 (88%) 309 (86.3%) 0.618
Surgical conditions 200 (11.1%) 65 (10.9%) 65 (13.8%) 42 (11.2%) 28 (7.8%) 0.162
Number of organ failures
0 1528 (84.9%) 527 (88.7%) 409 (86.7%) 305 (81.1%) 287 (80.2%) <0.001
1 228 (12.7%) 62 (10.4%) 53 (11.2%) 56 (14.9%) 57 (15.9%) 0.034
≥2 44 (2.9%) 5 (0.9%) 10 (2.4%) 15 (4.9%) 14 (4.9%) 0.003
Values are expressed as absolute count (percentage) and mean ± standard error mean. p-values: linear trend from
1997–1999 to 2008–2014 by the Extended Mantel–Haenszel Chi Square. Statistically significant differences are shown in bold.
4.2. Epidemiological Trends of Infective Endocarditis
The trends of the rates of IE in HIV-infected patients in Spain during the period from 1997 to 2014
are shown in Figure 2 (full description in Supplementary Table S3). We found significant downward
trends from 1997–1999 to 2008–2014 in the rate of hospital admissions with an IE diagnosis (from
21.8 to 3.8 events per 10,000 patients/year; p < 0.001), IE incidence (from 18.2 to 2.9 events per 10,000
patients/year; p < 0.001), and IE mortality (from 23.9 to 5.5 deaths per 100,000 patient-years; p < 0.001).
However, the case fatality rate (approximately 12.9%) did not change during follow up.
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Figure 2. Epidemiological trends of infective endocarditis in HIV-infected patients in Spain (1997
to 2014). (A) Hospital admissions. (B) Incidence; (C) Mortality; (D) Case fatality rate. Statistical:
Differences between groups were calculated by the Chi Square test. Linear trends from 1997–1999 to
2008–2014 calculated by he Ext nded Mantel–Haen l Chi Square.
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4.3. Epidemiological Trends of IE-Related Microorganisms
The trends in the rates of IE by type of microorganism in HIV-infected patients in Spain during
the period from 1997 to 2014 is shown in Figure 3 (full description in Supplementary Table S4).
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Figure 3. Epidemiological trends of causative microorganisms of infective endocarditis in HIV-infected
patients in Spain (1997 to 2014). (A) Staphylococcus aureus. (B) Coagulase-Negative staphylococci.
(C) Streptococci. (D) Gram-negative bacilli. (E) Enterococci. (F) Fungus. Statistical: Differences
between groups were calculated by the Chi Square test. Linear trends from 1997–1999 to 2008–2014
calculated by the Extended Mantel–Haenszel Chi Square.
Overall, the most frequent microorganisms involved were staphylococci (50%; 42.7% Staphylococcus
aureus and 7.3% CoNS), followed by streptococci (9.3%), Gram-negative bacilli (8.3%), enterococci (3%),
and fungus (1.4%). During the study period, the rates for Staphylococcus aureus remained consistent
without major changes, but we found a significant downward trend in the rate of CoNS (p < 0.001),
particularly between the first calendar period (1997–1999) and the other calendar periods. Moreover,
we found a significant upward trend in the rates of streptococci (p = 0.001), Gram-negative bacilli
(p < 0.001), enterococci (p = 0.003), and fungus (p < 0.001), mainly in 2008–2014. We also emphasize
that only 37 of S. aureus isolates were methicillin-resistant S. aureus (MRSA) and the MRSA rate (around
2%; 95% CI = 1.5%; 2.7%) did not have significant changes during the follow up.
4.4. Epidemiological Trends of IE According to Mode of Acquisition
The rates of IE stratified by mode of acquisition (community-acquired vs. health care-associated)
are shown in Figure 4 (full description in Supplementary Table S5).
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IE. Statistical: Differences between groups were calculated by the Chi Square test. Linear trends from
1997–1999 to 2008–2014 calculated by the Extended Mantel–Haenszel Chi Square.
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Overall, the rate of community-acquired IE showed a significant upward trend (from 46.5% to
51.4%; p = 0.001), while the rate of health care-associated IE showed a significant downward trend
(from 53.5% to 48.6%; p < 0.001), with the differences between the two modes of acquisition being
most prominent in the 1997–1999 (p = 0.016), 2000–2003 (p < 0.001), and 2004–2007 (p < 0.001) periods.
However, we found a significant change in trend between the periods 2004–2007 and 2008–2014,
both for community-acquired IE (p < 0.001) and health care-associated IE (p = 0.004). Furthermore,
we also analyzed the rates of IE-related microorganisms stratified by modes of acquisition (Figure 5;
full description in Supplementary Table S6). Overall, Staphylococcus aureus cases were more frequent in
the community-acquired IE (49.5% vs. 34.5%; p < 0.001), with these differences being more significant
in the 1997–1999 (p < 0.001), 2000–2003 (p < 0.001), and 2004–2007 (p = 0.014) periods.J. Clin. Med. 2019, 8, x FOR PEER REVIEW 8 of 12 
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Figure 5. Epidemiological trends of causative microorganisms of infective endocarditis in HIV-infected
patients in Spain (1997 t 2014) stratified by health care-associated and community-acquired endocarditis.
(A) Staphylococcu aureus. (B) Coagulase-Negative stap yloco ci. (C) Streptococci. (D) Gram-negativ
bacilli. (E) Enterococci. (F) Fungus. Statistical: Differences betwe n groups were calculat d by the Chi
Squ re test. Linear trends from 1997–1999 to 2008–2014 calculated by the Extend d Ma tel–Haensz l
Chi Square.
5. Discussion
In this retrospective study on PLWH, we analyzed the epidemiological changes in IE in Spain
during a 17-year period, from 1997 to 2014. Overall, we found downward trends in hospital
admissions, incidence, and mortality related to IE diagnosis, but we also found significant changes in
IE patient characteristics (age, substance abuse, comorbidities, predisposing factors, and number of
organ failures), mode of acquisition (community-acquired IE vs. health care-associated IE), etiology
(IE-related microorganisms), and coinfections (non-IE-related microorganisms). To our knowledge,
our study is the first report evaluating the nationwide epidemiological trends of IE in PLWH during
the cART era (1997–2014).
Regarding patient characteristics, we want to highlight that the prevalence of comorbidities,
predisposing factors, and number of organ failures higher than two were low in PLWH with a diagnosis
of IE; however, we found increases during the follow up in the prevalence of these characteristics and
we also found increases in age and substance abuse. We do not know exactly the number of active
intravenous drug users (IVDUs) because ICD-9-CM only has diagnosis codes that define substance use
disorders [20]. However, epidemiological data available in Spain indicate that the percentage of active
IVDUs of all HIV-infected patients has decreased on aggregate [21]. The most frequent coinfection
was HCV infection, and an upward trend of hepatitis B and HCV infection during follow up was
found. However, it should be noted that the Spanish MBDS only collects hepatitis serology data and,
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therefore, all patients exposed to HCV and HBV are included here (clarifiers, infected, and cured).
The percentage of subjects who resolve HBV and HCV infection spontaneously is high, particularly
in hepatitis B. In addition, the percentage of subjects cured of hepatitis C, who achieved sustained
virological response after antiviral therapy, has increased over the years. It is most likely that increased
life expectancy in HIV-infected patients with chronical viral infections and the emergence of more
effective treatments may be responsible for this increase in the prevalence of hepatitis C [22,23] and
hepatitis B [24,25]. Another relevant coinfection was mycobacteria, with a downward trend from 1997
to 2014, which is consistent with previously published data on the entire HIV population of Spain [26].
These epidemiological trends may be related to the increasing use of cART during the previous decades
in Spain [26], which has improved the immunological status of patients [27] and decreased their risk of
infections [28].
In our study, we found a downward trend in the rates of incidence and hospital admissions
related to IE in PLWH in Spain. It is very likely that the decrease observed in IE in our study may
be due to the widespread use of cART. In developed countries, one of the main factors that impacts
the risk for development of bloodstream infections is the availability of cART [29], which promotes
HIV suppression, immune recovery, and a lower risk of infections [9,30]. The Spanish National
Health System (NHS) provides free medical care to 99.5% of the Spanish population and the rate of
HIV-infected individuals on cART increased significantly over the study period [27], increasing the
proportion of patients with undetectable HIV viral load and high CD4 T-cells count, and decreasing
the number of patients in an advanced clinical stage [27]. Also, during the follow-up period, cART has
improved its effectiveness [31], and due to simpler and less toxic drugs, adherence has increased [32],
which could have contributed to a decrease in the IE risk. Despite this, our data on IE incidence
in Spanish PLWH was 10 times higher than in the Spanish general population in the last calendar
period [3]. HIV-infected patients on suppressive cART are still a “fragile” population with an increased
risk for acquiring IE [12], since subjects with CD4+ T-cells count > 500 cells/µL continue to be at
risk of infection compared to patients with CD4 count > 750 cells/µL [15]. Moreover, Tsabedze et al.
reported in a recent article that the prognosis of IE in HIV-infected patients is similar to that for their
HIV-negative counterparts, but HIV-positive patients with low CD4 counts still have a higher mortality
rate [33]. In our study, the IE mortality decreased during follow up, as the IE incidence decreased.
This trend in IE mortality is clearly influenced by a decrease in the number of IE cases. However, the
case fatality rate did not change during the study period, and these values were slightly lower than
values recently reported in the Spanish general population, with the same database (MBDS), and a
similar follow-up period [3]. Therefore, although HIV-infected patients were at higher risk for IE, their
mortality was not higher than the general population.
Regarding the microbiological profile of IE episodes, we found that the most frequent
microorganisms involved in incident IE were staphylococci, particularly Staphylococcus aureus, followed
by streptococci, Gram-negative bacilli, enterococci, and fungus. In this study, we could only
analyze streptococcal infections without specifying species, such as Streptococcus viridans, because this
microorganism does not have a specific ICD-9 code. For this reason, we included ICD-9 codes for group
A, B, C, and G streptococci, as well as unspecified streptococcal infections. Despite this, we think most
of the streptococci were Streptococcus viridans, since the microbiological profile of IE supports it [34].
A main factor that influences the epidemiology of IE is the geographic distribution of some
pathogens [34]. In this sense, our data are not consistent with a recent report on the Spanish general
population [3] or with most of the studies published in Europe [34]. In relation to the Spanish general
population, Olmos et al. [3] found in the Spanish MBDS that the rates of S. aureus and streptococci
had a downward trend from around 20 and 23% at baseline (2003) to approximately 15 and 19% at
the end of follow up (2014), respectively. In our study, we found that the rate of S. aureus was higher
(approximately 43%) and had not changed significantly during the follow up, and the streptococci
rate was lower (approximately 10%) and with a more significant upward trend during follow up.
In addition to this, Olmos et al. [3] found a significant upward trend in the CoNS rate while we found
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that the CoNS rate in PLWH remained stable during the same period. Another notable difference was
that Olmos et al. [3] found an enterococci rate of approximately 13%, which exceeds 15% at the end of
the follow up, double what was found in our data. All these differences indicate that HIV-infected
patients and the general population had a different distribution of IE-related microorganisms in Spain.
Staphylococci infections are frequent among HIV-infected active IVDUs with IE, particularly
in the community-based setting [34]. In our study, S. aureus was by far the most commonly
isolated microorganism among community-acquired cases, but this difference with respect to health
care-associated cases disappeared in the last calendar period. Additionally, the decline in the CoNS rates
found in our study could have been related to the decrease in the rate of active IVDUs among Spanish
HIV-infected patients [21]. The rise in the rates of streptococci, Gram-negative bacilli, enterococci,
and fungus could be related to the greater use of health care–related interventional procedures in
recent years. However, when we performed an analysis of the IE-related microorganisms stratified by
health care-associated and community-acquired IE, we did not find significant differences in these four
groups of microorganisms.
6. Study Limitations
Firstly, our study was retrospective, using an administrative database (MBDS). This entails a series
of limitations that could have caused a confusion bias: (i) an absence of relevant information such as
treatments, definite and possible IE episode, therapeutic procedures, prognostic scores (Child Pugh
Turcotte (CPT), Model for End-stage Liver Disease (MELD), or Acute Physiology and Chronic Health
Evaluation (APACHE), or Sequential Organ Failure Assessment (SOFA)), previous hospitalizations,
etc.; (ii) we did not have data on the potential accuracy of the Spanish MBDS for IE-related diagnoses,
but given the specific features and relevance of IE, incorrect coding should be less likely than for other
diseases; (iii) a lack information related to the type of acquisition (nosocomial, community acquired),
which was implemented based on the timing of the IE code (main or secondary diagnosis); (iv) there
was a lack of microbiological information in 30% of hospital admissions (culture-negative or not
recorded), and consequently, the rates may be underestimated; (v) MBDS data are anonymous and it
is difficult to identify whether a patient has been hospitalized more than once in different hospitals,
but we performed an analysis of patient codes and dates of admission and discharge to detect hospital
changes or re-admissions with IE; (vi) no data were available from a significant percentage of private
hospitals, so the rates may be underestimated. However, these private centers represent a small
percentage of the total centers in Spain.
Secondly, we did not have data on the total number of PLWH in Spain between 1997 and 2014,
because there were no data on the national coverage of HIV diagnoses during this period. Instead,
we used estimates of the number of PLWH provided by the National Centre of Epidemiology (NCE,
Instituto de Salud Carlos III, Madrid, Spain), but without stratifying by gender and age. Therefore,
we could not calculate the rates stratified by gender and age.
Thirdly, our data were recorded before 2014 (more than four years ago) and our findings may not
reflect the current characteristics and outcomes related to IE.
7. Conclusions
Our data show that the rates of hospital admissions, incidence, and mortality related to IE diagnosis
in PLWH in Spain decreased from 1997 to 2014, while other changes in clinical and epidemiological
characteristics, mode of acquisition, and pathogens occurred over this time.
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